>Abituzumab VH (threshold 0.43)
QVQLQQSGAEVNKPGASVKLSCKASGYTFTSFWMHWVRQAPGQGLEWIGYINPRSGYTEYAEIFRDKATLTADKSISTAYMELSSLTSEDSAVYYCARFLGRGAMDYWGQGTSVTVSS
>Abituzumab VL (threshold 0.619)
DIQMTQTTSSLSASLGDRVTISCRASQDISNYLAWYQQLPDGTIKLLIYYTSKIHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTFPYTFGGGTKLEIK
>Afutuzumab VH (threshold 0.83)
QVQLVQSGPEVKKPGASVKVSCKASGYAFSYSWINWVRQAPGQGLEWIGRIFPGDGDTDYAGKFQGKLTLTWDKSTSTAYMHLSSLTSVDSAVYFCARNVFDGYWLVYWGQGTLVTVSS
>Afutuzumab VL (threshold 0.562)
DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIK
>Alacizumab VH (threshold 0.935)
QVKLVESGGDLVKPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVSVITSGGSYTYYVDSVKGRFTISRDNAKNTLYLQMSSLKVEDTAVYYCARIGEDALDYWGQGTLVTVSS
>Alacizumab VL (threshold 0.6859999999999999)
DIQMTQSPSSLSATLGERVSLTCRASQDIAGSLNWLQQEPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLAISSLESEDFVDYYCLQYGSFPPTFGGGTKLEIK
>Alemtuzumab VH (threshold 0.835)
DVMLVESGGGLVQPGGSLSLSCAASGFTFTDFYMNWVRQAPGKGLEWVGRIRDKAKGYTTEYAPSVKGRFTILRDNSKSILYLQMNSLRAEETAVYYCAREGHTAAPFDYWGQGSTVTVSS
>Alemtuzumab VL (threshold 0.8420000000000001)
SIKLIQSQASLSASLGETVTLTCKASQNIDKYLNWYQQKQGKSPKLLVYNTNNLQTGVPSRFSGSGSGTQFSLKINSVQTEDFGNYYCLQHISRPRTFGGGTKLEIK
>Anrukinzumab VH (threshold 0.88)
QVQLVQSGAEVKKLGGSVKVSCKASGFTFSSYAFSWVRQTPGQRLEWVAWISSGGNTYYPQSVHGRFTISRDMATNTLYLEMSSLKSEDTAMYYCARLDGYYFGFAYWGQGTLVTVSA
>Anrukinzumab VL (threshold 0.809)
DIVLTQSPASLAVSLGQRATISCKASESVDNYGKSLMHWYQQLPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLGINPVEADDIATYYCQQSNEDPWTFGGGTKLEIK
>Atezolizumab VH (threshold 0.975)
QVQLVESGGGLVQPGRSLGLSCAASGFTFSDSWIHWVRQAPGKGREWVAWISPYGGSTYYADSVKGRFTIFRDVAKNTLYLQMNSLRVEDTAVYYCARRHWPGGFDYWGQGTLVTVSS
>Atezolizumab VL (threshold 0.941)
SIVMTQSHKFMSASVGDRVSITCRADQDVSTAVAWYQQKPGQSPKLLIYSASFLYSGAPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYLYHPATFGGGTKLEIK
>Bapineuzumab VH (threshold 0.97)
QVQLVQSGAEVKAPGASVKVSCKASGFTFSNYGISWVRQVPGQGLEWMTWIRSGGGRTGYSQNVQGRVTITRDNAKNTQYLEMDSLRSEDTATYYCVRYDHYSGSSDYWGQGVMVTVSS
>Bapineuzumab VL (threshold 0.6579999999999999)
DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGGGTKLEIK
>Bemarituzumab VH (threshold 0.745)
QVQLAQSGAEVKKPGASVKMSCKASGYTFTTYNVHWVRQAPGQGLEWMGSIYPDNGDTSYAQNFQGKVTLTADKSSSTAYMELSSLTSEDSAVYYCARGDFAYWGQGTLVTVSA
>Bemarituzumab VL (threshold 0.725)
SIVMTQSHKFMSTSVGDRVSITCKASQGVSNDVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHSTTPYTFGGGTKLEIK
>Benralizumab VH (threshold 0.61)
QVQLVQSGPEVNKPGASVKVSCKASGYTFTSYVIHWVRQAPGQGLEWIGYINPYNDGTKYAERFKGKLTLTSDKSISTAYMELSSLTSEDSAVYLCGREGIRYYGLLGDYWGQGTSVTVSS
>Benralizumab VL (threshold 0.981)
DSVMTQTTSSASATLGDRVTISCSGSEDIINYLNWYQQLPDGTVKLLIYHTSRLQSGVPSRFSGSKSGTSYSLDISNLEQEDIATYFCQQGYTLPYTFGGGTKLEIK
>Bevacizumab VH (threshold 0.81)
QIQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGKGLKWMGWINTYTGEPTYAAKFQRRVAMSTETSASTAYMELNNLKFEDMATYFCARYPHYYGSSHWYFDVWGAGTTVTVSS
>Bevacizumab VL (threshold 0.899)
DIQMTQTTSSLSAALGDRVTISCSASQDISNYLNWYQQLPDGTVKLLIYFTSSLHSGVPSRFSGSGSGTSYFLTISNLEPEDIATYYCQQYSTVPWTFGGGTKLEIK
>Blosozumab VH (threshold 0.985)
QVQLLQSGAELKRPGASVKVSCAASGFNIKDTFQHWVRQAPGQGLEWMGWSDPEIGDTEYAQKFQGRVTITADTSINTAYMELSSLTSDDTAVYYCTTGDTTYKFDFWGQGTMLTVSS
>Blosozumab VL (threshold 0.8420000000000001)
SIVMTQSHKFMSTSVGDRVSITCKASQDVHTAVAWYQQKPGQSPKLLIYWASTRWTGVPDRFTGSGSGTDFTLTISNLQSEDLADYFCQQYSDYPWTFGGGTKLEIK
>Bococizumab VH (threshold 0.87)
QVQLIQPGAELKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLDWMGEISPFGGRTNYAEKFQSKVTLTVDTSISTAYMELSSLTSEDSAVYYCARERPLYASDLWGQGTSVTVSS
>Bococizumab VL (threshold 0.9009999999999999)
SIVMTQSHKSMSVSVGDRVSITCRASQGISSALAWYQQKPGQSPKLLIYSASYRYTGAPGRFTGSGSGTDFTFTISSVQAEDLAVYYCQQRYSLWRTFGGGTKLEIK
>Brontictuzumab VH (threshold 0.735)
QVQLIQSGAEVKKPGASVKLSCKATGYTFTGYWIEWVRQAPGHGLEWIGQILPGTGRTNYAEKFQGRATFTADTSITPAYMPLSSLTTEDSAIYYCARFDGNYGYYAMDYWGQGTSVTVSS
>Brontictuzumab VL (threshold 0.72)
EAVVTQESALTTSPGETVTLSCRSSTGAVTTSNYANWVQQKPDQLFTGLIGGTNNRAPGVPARFSGSLIGGKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL
>Cabiralizumab VH (threshold 0.89)
QVQLVQSGPEVKKPGASVKVPCKASGYTFTDNYMIWVRQAHGKSLEWIGDINPYNGGTTFAQKFQGRGTLTVDKSISTAYMELRSLTSEDTAVYYCARESPYFSNLYVMDYWGQGTSVTVSS
>Cabiralizumab VL (threshold 0.78)
DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDNYMNWYQQLPGQPPKLLIYAASNLESGIPARFSGSGSGTSFTLNIHPVEEEDAATYYCHLSNEDLSTFGGGTKLEIK
>Camrelizumab VH (threshold 0.88)
QVQLVQSGAEVKKPGGSLKVSCKASGFTFSSYMMSWVRQTPEQRLEWMAWISGGGANTYYPQSVAGRVTITRDAATNTLYLEMSSLRSEDTALYYCARQLYYFDYWGQGTTLTVSS
>Camrelizumab VL (threshold 0.8859999999999999)
SIQMTQSPASQSASLGESVTITCLADQTIGTWLTWYQQKPGKSPQLLIYTATSLADGVPSRFSGSGSGTKFSFKISSLQAEDFVSYYCQQVYSIPWTFGGGTKLEIK
>Cantuzumab VH (threshold 0.29)
QIQLVQSGPEVKKPGETVKISCKASDYTFTYYGMNWVRQAPGKGLKWMGWIDTTTGEPTYAQKFQGRFAMSLETSASTAYLQIKNLKNEDTATYFCARRGPYNWYFDVWGAGTTVTVSS
>Cantuzumab VL (threshold 0.182)
DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLVSGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCLQHLEYPFTFGGGTKLELK
>Cergutuzumab VH (threshold 0.98)
QVQLVQSGAEAKKPGASVKVSCCASGYTFTEFGMNWVRQAPGQGLKWMGWINTKTGEATYVEEFQGRVAMTMDTSLSTVYMEIRNLKAEDMATYFCARWDFAYYVEAMDYWGQGTTVTVSS
>Cergutuzumab VL (threshold 0.887)
SIVMTQSQQFVSVSVGDRASVTCKASAAVGTYVAWDQQKPGQAPKALMYSASYRKRGVPDRFTGSGSGTDFTLTISNGQSEDLAEYFCHQYYTYPLFTFGSGTKLEIK
>Certolizumab VH (threshold 0.855)
EVQRVESGGRLKKPGETLRGSCKASGYVFTDYGMNWVRQAPGKGLKWVSVINTYIGEPIYADSVKGRFAISRETSASTAYLQINNLKAEDTAVYFCARGYRSYAMDYWGQGTLVTVSS
>Certolizumab VL (threshold 0.862)
SIVMTQSQTSMSVSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASFLYSGVPYRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNIYPLTFGAGTKLELK
>Citatuzumab VH (threshold 0.455)
QIQLVQSGGEVKKPGETVRISCKASGYTFTNYGMNWVKQAPGKALKWMSWINTYTGESTYADSVKGRFAFSLEPSKSAAYLQINNLNNEDTAVCFCARFAIKGDYWGQGTTLTVSS
>Citatuzumab VL (threshold 0.787)
DIVMTQVASSNPVTLGTSASISCRSTKSLLHSNGITYLYWYLQHPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLEIPRTFGGGTKLELK
>Clivatuzumab VH (threshold 0.515)
EVQLQQSGPELKKPGASVKMSCKASGYTFPSYVLHWVRQAPGQGLEWMGYINPYNDGTQYAEKFQGKATLTSDKSISTAYMELSSLTSEDSAVYYCARGFGGSYGFAYWGQGTLVTVSA
>Clivatuzumab VL (threshold 0.82)
QIVLTQSPSIMSASPGEKVTMTCSASSSVSSSYLYWYQQLPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAASYFCHQWNRYPYTFGGGTKLEIK
>Codrituzumab VH (threshold 0.965)
QVQLVQSGAEVKRPGASVTVSCKASGYTFTDYEMHWVRQAPVHGLEWIGALDPKTGDTAYSQKFQGRVILTADTSISTAYMELRSLTSEDTAVYYCTRFYSYTYWGQGTTVTVSS
>Codrituzumab VL (threshold 0.738)
DSVMTQTPLSLPVSLGDQASISCRSSQSLVHSNRNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQNTHVPPTFGGGTKLEIK
>Cofetuzumab VH (threshold 0.795)
QVQLFQSGGGVVRPGVSLRISCVGSGYTFTDYAVHWVRQAHAKSLEWVSVISTYNDYTYNADSMKGAATNTRDNSSSTDYMEMARLTAEDTAINYCARGNSYFYALDYWGQGTRVTVSS
>Cofetuzumab VL (threshold 0.76)
EIVLTHSPASLPVTLGLRATISCRASESVDSYGKSFMHWYQQLPGQPPKLLIYRASNLESGVPARFSGSGSRTDFTLTINRVEADDVATYYCQQSNEDPWTFGGGTKLEIK
>Concizumab VH (threshold 0.445)
QVQLVESGGGVKKPGGSLKLSCKASGFTFSNYAMSWVRQTPEQRLEWMATISRSGSYSYFPQSVQGRFTISRDNAKNTLYMQMSSLRSEDTAMYYCARLGGYDEGDAMDSWGQGTSVTVSS
>Concizumab VL (threshold 0.8740000000000001)
DSVMTQTPLTLSVTIGQRASISCKSSQSLLESDGKTYLNWLLQRPGESPKLLIYLVSILDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCLQATHFPQTFGGGTKLEIK
>Crenezumab VH (threshold 0.865)
QVELVQSGAGVKKPGASVKVSCRASGFTFSSYGMSWVRQTPDPRLELMGWINSNGGSTYYPQKVCGRLTISRDMAKNTLYLGMSSLRSEDTAMYYCASGDYWGQGTTLTVSS
>Crenezumab VL (threshold 0.826)
DIAMTQSALSLPVSLGDQASISCRSSQSLVYSNGDTYLHWYLQAPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIK
>Crizanlizumab VH (threshold 0.86)
QVQLVQSGPEVNKPGALVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGWIYPGDGSIKYAEKFQGRLTLTADKSSSTAYMELSSLTSENSAVYFCARRGEYGNYEGAMDYWGQGTSVTVSS
>Crizanlizumab VL (threshold 0.875)
QIVMTQSPASLAVSLGQRATISCKASQSVDYDGHSYMNWYQQLPGQPPKLLIYAASNLESGIPARFSGSGSGTSFTLNIHPVEEEDAATYYCQQSDENPLTFGGGTKLEIK
>Dacetuzumab VH (threshold 0.81)
QVQGVESGPDVKKPGASVKISCKASGYSFTGYYIHWVRQAPGKSLEWMGRVIPNAGGTSYAQKFQGRLILTVDKSSSTAYMELRSLTSEDSAVYYCAREGIYWWGQGTTLTVSS
>Dacetuzumab VL (threshold 0.759)
DIVMTQTPLSLSVSLGDQVSISCRSSQSLVHSNGNTFLHWYLQDPGQSPKLLIYTVSNRFSGVPDSFSGSGSGTDFTLKISRVETEDLGVYFCSQTTHVPWTFGGGTKLEIK
>Daclizumab VH (threshold 0.65)
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYAQKFQDKATLTWDKSISTAYMQLSSLTSDDSAVYYCARGGGVFDYWGQGTTLTVSS
>Daclizumab VL (threshold 0.903)
QIVLTQSPAIMSAIPGEKVTMTCSASSSISYMHWYQQLPGTSPKRWIYTTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSTYPLTFGAGTKLEVK
>Dalotuzumab VH (threshold 0.99)
QVQLQQWGPGLVKPSETLSLTCSVYGYSITGGYLWNWIRQHPGEGLEWIGYISYDGTNNYKPSLKDRGSISIDTSKNQFSLKLTSVTTADTAVYYCARYGRVFFDYWGQGTTLTVSS
>Dalotuzumab VL (threshold 0.75)
DIAMTQSALSLPVSLGDQASISCRSSQSIVHSNGNTYLQWYLQAPGQSPKLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPWTFGGGTKLEIK
>Dapirolizumab VH (threshold 0.715)
EVQLVQSGPEVKQSSETLSLHCTVSGFSSTNYHVGWVRQMPGKGLEWMGVIWGDGDTSYNSVLKSHLSISADTSISQAFLKWNSLQASDTATYYCARQLTHYYVLAAWGQGAQVTVSS
>Dapirolizumab VL (threshold 0.882)
SIQMTQTTSSMSVSLGDRATISCRASEDLYYNLAWYQRKPGQSVKLLIYDTYRLADGVPSRFSGSGSGADYSLTISSLEPEDVASYYCQQYYKFPFTFGAGTKLEIK
>Demcizumab VH (threshold 0.685)
QVQLVQSGPELKKTGASVKISCKASGYSFTAYYIHWVRQAHGKSLEWIGYISSYNGATNYAQKFQGKLTFTVDTSISTAYMELSSLTSEDSAVYYCARDYDYDVGMDYWGQGTSVTVSS
>Demcizumab VL (threshold 0.58)
DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSKEVPWTFGGGTKLEIK
>Denintuzumab VH (threshold 0.83)
QVQLVQSGPAVKQPGATLSVSCQFSGFSLSTSGMGVGWIRQASGQGLEWLAHIWWDDDKRYAPKLQSRVTITADTSSNQVFLKIASVDTADTATYYCARMELWSYYFDYWGQGTLLTVSS
>Denintuzumab VL (threshold 0.835)
QIVLTQSPAIMSATPGEKVTMTCSASSSVSYMHWYQQLPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDVATYYCFQGSVYPFTFGSGTKLEIK
>Dezamizumab VH (threshold 0.845)
QVQLVQPGAEVKKPGASVKVSCKASGYTFTTYNMHWVRQAPGQGLEWMGYIYPGDGNANYAQQFQGRATLTADKSSSTAYMQLSSLTSEDSAVYYCARGDFDYDGGYYFDSWGQGTTLTVSS
>Dezamizumab VL (threshold 0.5670000000000001)
DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQLLVHNAKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHHYGAPLTFGAGTKLELK
>Domagrozumab VH (threshold 0.97)
QVKQVQSGAEAKKPGASVKVSCQASGFTFSSYAMSWVRQTPGQRLEWMCWISSGGSYTEYPQSAQGRVTITRDIAKNTAYLDLSSLRSEDTAMYYCAKQDYAMNYWGQGTLVTVSS
>Domagrozumab VL (threshold 0.7040000000000001)
DIVMTQSPKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPWTFGGGTKLEIK
>Duligotuzumab VH (threshold 0.94)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSGDWIHWVRQTPGKGLEWVSEISAAGGYTDYADSVKGRFTISRDNAKNNLYLQMSSLKVEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS
>Duligotuzumab VL (threshold 0.988)
SIVMTQSTKFMSVSVGDRVSVTCRADQNIATDVAWYQQKPGQSPKALIYSASFLYSGVPDRFTGSGSGTGFTLTISNVQSMDLAEYFCQQSEPEPYTFGGGTKLEIK
>Eculizumab VH (threshold 0.975)
QVQLVQSGAEVMKPGASVKVSCKATGYTFSNYWIQWVRQAPGHGLEWMGWILPGSGSTEYAENFQDRATITADTSINTAYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGAGTTVTVSS
>Eculizumab VL (threshold 0.893)
SIQMTQSPASLSVSVGETVTITCGASENIYGALNWYQRKQGQSPQLLIYGATNLADGMSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLNTPLTFGAGTKLELK
>Efalizumab VH (threshold 0.76)
QVQLIQSGAEVKRPGASVKVSCKASGYSFTGHWMNWVRQVPGQGLEWMGMIHPSDSETRYAQKFQDKATLTWDKSISTAYMELSSPTSEDSAVYYCARGIYFYGTTYFDYWGQGTTLTVSS
>Efalizumab VL (threshold 0.494)
DVQITQSPSYLAASPGETITINCRASKTISKYLAWYQEKPGKTNKLLIYSGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPLTFGAGTKLELK
>Elotuzumab VH (threshold 0.375)
QVQLVESGGGVKQPGGSLKLSCAASGFDFSRYWMSWVRQAPGQGLEWMGEINPDSSTINYAPSLKDKFIITRDNAKNTLYLEMSKVRSEDTALYYCARPDGNYWYFDVWGAGTTVTVSS
>Elotuzumab VL (threshold 0.8059999999999999)
SIVMTQSHKFMSTSVGDRVSITCKASQDVGIAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPYTFGGGTKLEIK
>Emactuzumab VH (threshold 0.995)
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDGGTNYAQKLQGRVTLTVDTSISTAYMELSSLTSEDTAVYYCARDQRLYFDVWGTGTTVTVSS
>Emactuzumab VL (threshold 0.966)
SIVMIQSPKSMSVSVGERVTLSCRAHEDVNTYVSWYQQKPEQSPQLLIYAASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCQQSFSYPTFGGGTKLEIK
>Emibetuzumab VH (threshold 0.945)
QVQLVQSGAEVKKPGASVKISCKASGYTFTDYYMHWVRQSHGKSLEWMGRVNPNRRGTTYAQKFQGAVTLTADKSISTAYMELSSLTSEDSAVYYCARANWLDYWGQGTTVTVSS
>Emibetuzumab VL (threshold 0.898)
QNVLTQSPAIMSATPGEKVTMTCSVSSSVSSIYLHWYQQLSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQVYSGYPLTFGGGTKLEIK
>Emicizumab VH (threshold 0.865)
QVQLVQSGAEVKKPGASVKIPCKASGYTFTDNNMDWVRQAPGKSLEWIGDINTRSGGSIYAEEFQDKVTLTVDKSISTAYMELRSLTSEDTAVYHCARRKSYGYYLDEWGEGTTVTVSS
>Emicizumab VL (threshold 0.872)
SIQMNQSPSSLSASLGDTITITCKASRNIERQLAWYQQKPGQSPKLLIYQASRKESGVPDRFTGSRYGTDFTLTISNVQSEDLADYFCQQYSDPPLTFGAGTKLELK
>Enavatuzumab VH (threshold 0.71)
EVQVVESGGGLVQPGGSLRLSCVASGFTFSSYWMSWVRQAPGKGLEWVSTIRLKSDNYATHYAESVKGKFTISRDDSKNRLYLQMNSLRAEDTGVYYCTTYYADAMDYWGQGTLVTVSS
>Enavatuzumab VL (threshold 0.813)
DIVLTQSPASLAVTLGQRVTISCRASQSVSTSSYSYMHWYQQLPGQPPKLLIKYASNLESGVPARFSGSGSGTSFTLNIHPVEEEDTATYYCQHSWEIPYTFGGGTKLEIK
>Enoblituzumab VH (threshold 0.885)
QVQLVQSGGEVKQPGGSVKVSCAASGFTFSSFGFHWVRQAPEQGLEWMAYISSDSSAIYYAQTVQGRFTISRDKPINTAFLEMTSLRSEDTAMYYCGRGRENIYYGSRLDYWGQGTSVTVSS
>Enoblituzumab VL (threshold 0.88)
SIVMTQSQKFMSASVGDRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNNYPFTFGSGTKLEIK
>Enokizumab VH (threshold 0.84)
QVQLIQSGAEVNKPGASVKVSCKATGYTFSYYWIEWVRQAPGHGLEWIGEILPGSGTTNPAQKFFGRVTFTWDTSINTAYMGLSSLTSEDTAVYYCARADYYGSDYVKFDYWGQGTTLTVSS
>Enokizumab VL (threshold 0.9359999999999999)
SYVMTQSQIFMSVSVGDRVTVTCKASQHVITHVTWYQQKPGQSPKALIYGTSYSYSGVPNRFTGSGSGTDFTLTISNVQSEDLAEYFCQQFYEYPLTFGAGTKLELK
>Epratuzumab VH (threshold 0.64)
QVQLQQSGAELKRPGTSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWMGYINPRNDYTEYAQNFQDKATLTWDTSISTAYMELSSLTSDDSAFYYCARRDITTFYWGQGTTLTVSS
>Epratuzumab VL (threshold 0.66)
NIMMTQSPSSLAVSVGERVTMSCKSSQSVLYSANHKNYLAWYQQHPGQSTKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCHQYLSSWTFGGGTKLEIK
>Etaracizumab VH (threshold 0.94)
QVQRVQSGGEVKKPGGSVKVSCKASGFAFSSYDFSWVRQTPGQRLEWMGKVSSGGGSTYYLQTVQGRFTISRDWAANTLYMEASSLKSEDTAMYYCARHLHGSFASWGQGTLVTVSA
>Etaracizumab VL (threshold 0.95)
SIVLTQSTATLSVTPGDRVSLSCQASQSISNFLHWYHQKSGESPRLLIRYRSQSISGIPSRFSGSGSGTDFTLTINSVETEDFGVYFCQQSGSWPLTFGGGTKLELK
>Farletuzumab VH (threshold 0.79)
QVQLVESGGDLVKPGGSLRLSCAASGFTFSGYGLSWVRQAPGKGLEWVSMISSGGSYTYYADSVKGRFAISRDNAKNTLYLQMSSLKVEDTAMYYCARHGDDPAWFAYWGQGTPVTVSS
>Farletuzumab VL (threshold 0.789)
EIVLTQSPALMAASPGEKVTITCSVSSSISSNNLHWYQQLSETSPKPWIYGTSNLASGVPVRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSYPYMYTFGGGTKLEIK
>Fibatuzumab VH (threshold 0.97)
QVQLVQPGAEVKKPGASVKVSCKASGYTFTGYWINWVRQAPGQGLEWMGDIYPGSGNTNYAEKFQGRVTMTEDTSISTAYMDLSSLTSDDSAVYYCARGGYYEDFDSWGQGTTLTVSS
>Fibatuzumab VL (threshold 0.993)
HSAMTQCASSASGSLGQSVSLACRATQGIISYLAWLQQHPEGAIKIAIYAASSRQSGVSKRFSGSRSGSTYSLTISSLESEDFADYYCGQYANYPYTFGGGTKLEIK
>Ficlatuzumab VH (threshold 0.73)
QVQLVQPGTEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWMGEINPTNGHTNYAQKFQGKATLTVDKSISTAYMALSSLTSEDSAVYYCARNYVGSIFDYWGQGTTLTVSS
>Ficlatuzumab VL (threshold 0.51)
NIVMTQSPKSMSMSVGERVTLSCKASENVVSYVSWYQQKTEQSPKLVIYGASNRESGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQSYNYPYTFGGGTKLEIK
>Flotetuzumab VH (threshold 0.705)
EVQLIQSGPEVKKPGASVKISCKASGYTFTDYYMKWVRQAHGKSLEWMGDIIPSNGATFYAQKFQGKATLTVDKSISTAYMELRSLRSEDSAVYYCARSHLLRASWFAYWGQGTLVTVSA
>Flotetuzumab VL (threshold 0.795)
DFVMTQSPSSLAVAAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQLPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPYTFGGGTKLEIK
>Fontolizumab VH (threshold 0.405)
QVQLKQPGAELKRPGSSVKLSCKASGYTFTSSWINWVKQAPIQGLEWMGRIDPSDGEVHYAQDFQDKATLTVDKSISTAYMQLSSLTSEDSAVYYCARGFLPWFADWGQGTLVTVSA
>Fontolizumab VL (threshold 0.932)
SIVMTQSPKSMSVSIGERVTLSCKAEENVDTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQSYNYPFTFGGGTKLEVK
>Fremanezumab VH (threshold 0.875)
EVKLVESGGGLVQPGGSMRLSCVASGFTFSNYWISWVRQAPGKGLEWVSRIRSESDASATHYAEAVKGRFTISRDDSKSIVYLQMNSLRAEDTGVYYCLAYFDYGLAIQNYWGQGTLVTVSS
>Fremanezumab VL (threshold 0.98)
SYEMTQSPKSMSVSVGERDSLICKASKRVTTYVSWYQQKPEQSPKLLIYGASNRYLGVPDRFTGSGSATYFTLTISSVQAEDLADYHCSQSYNYPYTFGAGTKLEIK
>Galcanezumab VH (threshold 0.945)
QVQLVQSGAEVKRPGTSVKVSCKASGYTFTNYWMQWARQAPGHGLEWMGIIYEGTGKTVYIQKFQDKVTITADKSTSTAYMAFSSLRSEDAAIYYCARLSDYVSGFGYWGQGTLLTVSS
>Galcanezumab VL (threshold 0.741)
DIQMTQTTSSLSASVGDRVTISCRASKDISKYLNWYQQLPDGTVKLLIYYTSGYHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGDALPPTFGGGTKLEIK
>Gatipotuzumab VH (threshold 0.74)
QVQLVQSGAEVKQPGASMKVSCVASGFTFSNYWMNWVRQSPEQGLEWVAEIRLKSNNYTTHYAESVQGRVTISRDDSTSSVYLDMNNLRAEDTGIYYCTRHYYFDYWGQGTTLTVSS
>Gatipotuzumab VL (threshold 0.608)
DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGGGTKLEIK
>Gemtuzumab VH (threshold 0.625)
EVQLIQSGPEGKKPGASVKISCKASGYTFTDSNIHWVRQSPGKSLEWMGYIYPYNGGTDYAQKFQNKVTLTVDNPISTAYMELRSLTSEDSAFYYCANGNPWLAYWGQGTLVTVSA
>Gemtuzumab VL (threshold 0.922)
DSVLTQSPSTLAVTAGQRATISCRASESLDNYGIRFLTWFQQLPGQPPKLLMYAASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQTKEVPWSFGGGTKLEVK
>Gevokizumab VH (threshold 0.4)
QVTLKESGPTILKPTQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKALEWLAHIWWDGDESYNPSLKSQLTISKDTSRNQVFLKITSVDPADTATYYCARNRYDPPWFVDWGQGTLVTVSA
>Gevokizumab VL (threshold 0.524)
DIQMTQTTSSLSASLGDRVTISCRASQDISNYLSWYQQKPDGTVKLLIYYTSKLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCLQGKMLPWTFGGGTKLEIK
>Ibalizumab VH (threshold 0.25)
EVQLQQSGPELRKPGASVKMSCKASGYTFTSYVIHWVKQAPGQGLDWIGYINPYNDGTDYDEKFQGKATLTSDKSISTAYMELSSLTSEDSAVYYCAREKDNYATGAWFAYWGQGTLVTVSA
>Ibalizumab VL (threshold 0.755)
DSAMTQSPSSLAVSVGEKVTMSCKSSQSLLYSTNQKNYLAWYQQPPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYRTFGGGTKLEIK
>Idarucizumab VH (threshold 0.765)
QVQLVQSGAGVKAPSSSVTITCQVSGFSLTSYIVDWVRQAPGQGLEWLGVIWAGGSTGYAQKLQSRLSISKDNSTSQVYLKMNSLQTDDTAMYYCASAAYYSYYNYDGFAYWGQGTLVTVSA
>Idarucizumab VL (threshold 0.9)
DSVMTQTPLTLSVTIGQRASISCKASQSLLYTDGKTYLYWLLQRPGQSPKRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCLQSTHFPHTFGGGTKLEIK
>Ifabotuzumab VH (threshold 0.97)
QVQLVQPGAEVKKPGASVKVSCKASGYTFTGYWINWVRQAPGQGLEWMGDIYPGSGNTNYAEKFQGRVTMTEDTSISTAYMDLSSLTSDDSAVYYCARGGYYEDFDSWGQGTTLTVSS
>Ifabotuzumab VL (threshold 0.993)
HSAMTQCASSASGSLGQSVSLACRATQGIISYLAWLQQHPEGAIKIAIYAASSRQSGVSKRFSGSRSGSTYSLTISSLESEDFADYYCGQYANYPYTFGGGTKLEIK
>Iladatuzumab VH (threshold 0.69)
QVQLGQPGAEVKKPGASVKISCKATGYTFSSYWIEWVRQAPGHGLEWIGEILPGGGDTNYAEIFQGEATFTWDTSINTAYMDLSSLTSEDTAVYYCARRVPIRLDYWGQGTLVTVSA
>Iladatuzumab VL (threshold 0.8590000000000001)
DIVMTQSPASLAVTLGQRATISCKASQSVDYEGDSFLNWFQQLPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLNIHPLEEEDAATYYCQQSNEDPLTFGAGTKLELK
>Imgatuzumab VH (threshold 0.995)
QVQLGQSGAEVKKPGASVKVSCKASGYTFTDYKIHWVRQAPGQGLEWMGYFNPNSGYSTYAQKFQGRVTLTADKSTSTAYMELSSLTYEDTAVYYCARLSPGGYYVMDAWGQGTSVTVSS
>Imgatuzumab VL (threshold 0.73)
SIKMHQSPPSLYPSLGARVTITCRASQGINNYLNWYQQKPGESPKTLIYNTNNLQTGVPSRFSGSGSGQDYSLTISNLEYEDMGIYYCLQHNSFPTFGGGTKLELK
>Inebilizumab VH (threshold 0.895)
QVQLRQSGPEVKPPGASVKVSCKASGYAFSSSWMNWVRQAPGKGLEWIGRIYPGDGDTNYAVKFQGRLTMTWDKSVSTAYMELSSLTSEDTAVYFCARSGFITTVRDFDYWGQGTTLTVSS
>Inebilizumab VL (threshold 0.655)
DIVLTQSPASQAVTLKQKATISCRASESVDTFGISFMNWFQQKPDQPPKLLIHEASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDAAMYFCQQSKEVPFTFGSGTKLEIK
>Inotuzumab VH (threshold 0.91)
QVQLVQSGTVVKRPGASVKVSCKASGYRFTNYWIHWVGQAPGQGLEWIGGINPGNNYATYRRKFQGRVKLTAVTSTSTAYMELSSLTNEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSA
>Inotuzumab VL (threshold 0.6970000000000001)
DVVVTQTPLSLSVSFGDQVSISCRSSQSLANSYGNTFLSWYLHLPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISTIKPEDLGMYYCLQGTHQPYTFGSGTKLEIK
>Itolizumab VH (threshold 0.07)
EVQLVESGGGVKKPGGSLKLSCAASGFKFSRYAMSWVRQTPEKRLEWVATISSGGSYIYYPDSVKGRFTISRDNVKNTLYLQMSSLRSEDTAMYYCARRDYDLDYFDSWGQGTTLTVSS
>Itolizumab VL (threshold 0.256)
DIKMTQSPSSTYASLGARVTITCKASRDIRSYLTWYQQKPWKAPKTLIYYATSLADGVPSRFSGSGSGQDYSLTISSLESDDTATYYCLQHGESPFTLGSGTKLEIK
>Ixekizumab VH (threshold 0.9)
QVQLIQSGPELKKPGASVKVSCKASGYSFTDYHIHWVRQAPGKGLEWMGVINPMYGTTDYAQRFQGRATLTVDQSISTAYMELNSLTSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSA
>Ixekizumab VL (threshold 0.8640000000000001)
DSALTQSTLSLPVSLGDSASISCRSSRSLVHSRGNTYLHWYLQAPGQSPKLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHLPFTFGGGTKLEIK
>Labetuzumab VH (threshold 0.605)
QVQLQESGGGVKQPGGSLKVSCAASGFDFSTYWMSWVRQAPGKGLEWIGWIHPDSSTINYAPKLQDKVIITRDNAKNTAYMDMSKVRSEDTALYYCATLYFGFPWFAYWGQGTPVTVSA
>Labetuzumab VL (threshold 0.8640000000000001)
SIVMTQSPKFMSTSVGDRVSITCKASQDVGTSVAWYQQKPGQSPKLLIYWTSTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSLYRSFGGGTKLEIK
>Lacnotuzumab VH (threshold 0.73)
QVQLQQSGPGVKKPSASVSVTCTVTDYSITSDYAWNWIRQAPGNKLEWMGWISYSGSTSYAPKLQSRVSITRDTSINQFFMQLNSVTTEDTATYYCARFDYAHAMDYWGQGTSVTVSS
>Lacnotuzumab VL (threshold 0.59)
DILLTQSPAILSVSPGEKVSFSCQASQSIGTSIHWYQQKTDGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDAADYYCQQINSWPTTFGGGTKLEIK
>Ladiratuzumab VH (threshold 0.995)
QVQLIQSGAEVKKPGASVKVSCTASGLNIEDYYMHWVRQAPAQRLEWAGAIDPENGDTEYGQKFQGRVTMTADTSINTAYMELSSLTSEDTAVYYCNVHNAHYGTWFAYWGQGTLVTVSS
>Ladiratuzumab VL (threshold 0.866)
DSLLTQTPPSLPGSPGDQASISCRSSQSLLHSSGNTYLSWYLQHPGQSPKPLIYKISTRFSGVPDRFSGSGSGTDFTLKISSVEAEDLGVYYCFQGSHVPYTFGGGTKLEIK
>Lambrolizumab VH (threshold 0.88)
QVQLVQSGVEVKKPGVSVKLSCKASGYTFTNYYMYWVRQAPGQDLEWMGGINPSNGGTNFAEKFQNRATPTVDSSISTAYMELKSLQFEDSAVYFCARRDYRFDMGFDYWGQGTTLTVSS
>Lambrolizumab VL (threshold 0.87)
DSALTQSPASLAGSLGQSATISCRASKGVSTSGYSYLHWYQQHPGQPPKLLIYLASYLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRDLPLTFGGGTKLEIK
>Lampalizumab VH (threshold 0.53)
EIQLVQSGAEVKKPGATVKVSCKASGYTFTNYGMNWVKQAPGKGLKWMGWINTYTGETTYADDFQGRVVMSADTSVSTAYLEINNLKNEDMATYSCEREGGVNNWGQGTMVTVSA
>Lampalizumab VL (threshold 0.764)
QTTVTQSPASLSMAIGEKVTIRCITSTDIDDDMNWYQQLPGEPPKLLISGGNTLRPGVPSRFSSSGYGTDFVFTIENMLSEDVADYYCLQSDSLPYTFGGGTKLEIK
>Landogrozumab VH (threshold 0.985)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYPMSWVRQAPGKGLEWVSAITSSGGSTYYSDTVKGRFTISRDNAKNTLYLQMNSLRVEDTAVYYCARLPDYWGQGTLVTVSS
>Landogrozumab VL (threshold 0.95)
QSVLTQSPAIVSATPGERVTMTCSASSSVSSSYLHWYQQLSGASPKLWIYSTSNLVAGVPARFSGSGSGTSYSLAISSLEAEDAATYYCQHHSGYHFTFGSGTKLEIK
>Lebrikizumab VH (threshold 0.7)
QVQLRQSGAEVRAPSSSVSVTCQVSGFSLTAYSVNWVRQAPGQGLEWLGMIWGDGKIVYASALQSRLSMSKDNSISQVFLKMNSLQTDDTARYYCARDGYYPYAMDNWGQGSSVTVSS
>Lebrikizumab VL (threshold 0.61)
DIVMTQSPASLAVSLGQRATISCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPRTFGGGTKLEIK
>Lifastuzumab VH (threshold 0.945)
QVQLVESGGGVVQPGKSLRLSCAASGFSFSDFAMSWVRQSPGMGLEWVATIGRVAFHTYYADSMKGRFIISRDNAKNTLYLQMDSLRVEETAVYYCARHRGFDVGHFDFWGPGTLVTVSS
>Lifastuzumab VL (threshold 0.725)
DSQMTQTPLSLPVSLGDQAAISCRSSETLVHSSGNTYLEWYLQHPGQSPKLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSFNPLTFGAGTKLELK
>Ligelizumab VH (threshold 0.79)
QVQLVQPGAEVKRPGSSVKLSCKASGYTFTWYWLEWVRQAPIHGLEWMGEIDPGTFTTNYAEKFQAKVTFTVDKSTSTAYMELSSLTSEDSAVYYCARFSHFSGSNYDYFDYWGQGTTLTVSS
>Ligelizumab VL (threshold 0.93)
SILLTQSPAILSVSPGERVSFSCRASQSIGTNIHWYQQKTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQSWSWPTTFGGGTKLEIK
>Lintuzumab VH (threshold 0.61)
QVQLVQSGAELKKPGASVKVSCKASGYTFTDYNMHWVRQSHGKSLEWIGYIYPYNGGTGYAQKFQSKVTLTVDNSISTAYMELRSLTSEDSAVYYCARGRPAMDYWGQGTSVTVSS
>Lintuzumab VL (threshold 0.8859999999999999)
DSVLTQSPASLAVTVGQRATISCRASESVDNYGISFMNWFQQLPGQPPKLLIYAASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPWTFGGGTKLEIK
>Lorvotuzumab VH (threshold 0.985)
QVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVSGISSGSFTIYYADSVKGRFTISRDNAKNTLFLQMNSLRVEDTAVYYCARMRKGYAMDYWGQGTLVTVSS
>Lorvotuzumab VL (threshold 0.924)
DSALTQTALSLPVSLGDSCSISCRSSQIIIHSDGNTYLEWYLQHPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPHTFGGGTKLEIK
>Lumretuzumab VH (threshold 0.96)
QVQLAQSGAEVKKPGASVKLSCKTSGFTFSSSYISWLRQAPGQGLEWMAWIYAGTGSPSYAQKLQGRCQLTVDTSISTAYMEFSSLRTEDSAIYYCARHRDYYSNSLTYWGQGTTLTVSS
>Lumretuzumab VL (threshold 0.975)
QSVMTQPPSSLSVTAGERVTMSCKSSQSVLNSGNQKNYLTWYQQLPGQPPKLLIYWASTRESGVPDRFTGSGSGTSFTLDISSVQAEDLAVYYCQSDYSYPYTFGGGTKLEIK
>Lutikizumab VH (threshold 0.885)
QVCLVQSGGEVKKPGSSVKVSCAASGFTFSRYDFSWVRQTPEQRLEGMGWISHGGAGTYYPDSVKGRVTISRDAAINNLYLDLSHLKSDDTAMYYCARGGVTKGYFDVWGTGTPVTVSS
>Lutikizumab VL (threshold 0.637)
SIQMTQSPASLSASVGETVTITCRASGNIHNYLTWYQQTQGKSPQLLIYNAKTLADGVPSRFSGSGSGTQYSLKINSLQPEDFGIYYCQHFWSIPYTFGGGTKLQIT
>Matuzumab VH (threshold 0.62)
QVQLVQSGAEVKKPGASVKLSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYAEKFQSKATLTVDKSMSTAYMQLSSLTSEDSAVYYCASRDYDYDGRYFDYWGAGTTVTVSS
>Matuzumab VL (threshold 0.821)
SIVLTQSPAILSASPGEKVTMTCSASSSVTYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSHIFTFGSGTKLEIK
>Mepolizumab VH (threshold 0.555)
QVQLRQSGPEVKAPSASLSVTCQVSGFSLTSYSVHWVRQPPGQGLEWLGVIWASGGTDYASKLMSRLSISKDNSKSQVCLKMNSLQIDDPAMYYCARDPPSSLLRLDYWGQGTPVTVSS
>Mepolizumab VL (threshold 0.97)
QIVLTQSPSSLSVAPGEKVTMSCKRSQSLLNSGNQKNYLAWYQQLPGTPPKLLIYGASTRESGVPDRFTGSGSGTDFTLAISSVQAEDLAVYYCQNVHSFPFTFGSGTKLEIK
>Milatuzumab VH (threshold 0.505)
QLQLVQSGSELKKPGATVKVSCKASGYTFTNYGVNWVRQAPGKGLQWMGWINPNTGEPTFDQGFAGRFAFSLETSVSTAYLQLTNLKNEDTATYFCSRSRGKNEAWFAYWGQGTLVTVSA
>Milatuzumab VL (threshold 0.8220000000000001)
DSVLTQSPLSLPGSLGDQASISCRSSQSLVHRNGNTYLHWYLQHPGQSPKLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSSHVPPTFGAGTKLEIK
>Mirikizumab VH (threshold 0.855)
QVQLVQSGPEVKKPGASVKVSCKASGYKFTRYVMHWVRQAPGQGLEWIGYINPYNDGTNYAEKFQGRATLTSDKSISTAYMELSSLTSEDSAVYYCARNWDTGLWGQGTLVTVSA
>Mirikizumab VL (threshold 0.889)
SIQMTQSPSSLSVSLGGRVTITCKASDHILKFLTWYQQKPGNAPRLLISGATSLETGIPSRFSGSGSGKDYTLSITSLQTEDVATYYCQMYWSTPFTFGSGTKLEIK
>Mogamulizumab VH (threshold 0.76)
QVQLVQSGAEVKKPGASVKVSCAASGFTFSNYGFSWVRQTPDQRLEWVAWISSASTYSYYPRSVRGRFTISRDNATNTLYLDMSSLKSEDTAMYYCGRHSDGNFAFGYWGQGTTLTVSS
>Mogamulizumab VL (threshold 0.792)
DSLMTQTPLSLPVSLGDQASISCRSSRNIVHINGDTYLEWYLQHPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSLLPWTFGGGTKLEIK
>Monalizumab VH (threshold 0.995)
QVQLVQSGAEVKKPGSSAKASCKASGYTFTSYWFNWVRQAPIQGLEWMGRIDPYDSETMYAQKAQGWLTLTVDKSISTAYMELSSLTSEDTAVYYCARGGYDFDVGTLYWFFDVWGTGTTVTVSS
>Monalizumab VL (threshold 0.515)
DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQLLIYNAKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHHYGTPRTFGGGTKLEIK
>Mosunetuzumab VH (threshold 0.67)
QVQLVQSGAEVNRPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWMAWIYPGDGNTKYAEKFKGKVTLTAEKSISTAYMQLSSLTSEDSAVYFCARDSYSNYYFDYWGQGTTLTVSS
>Mosunetuzumab VL (threshold 0.985)
QSAMTQPPSSLAGSAGEKVTMSCKSSQSLLNSRTRKNYLAWYQQDPGKSPKLVIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCTQSFILRTFGGGTKLEIK
>Motavizumab VH (threshold 0.905)
QVTLRVSGPTLLKPTEALTLTCSFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKMANGDPADTATYYCARDMIFNFYFDVWGTGTTVTVSS
>Motavizumab VL (threshold 0.8490000000000001)
SIVMTQSPAIMSASPGEKVTITCSASSRVGYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCFQGSGYPFTFGGGTKLEIK
>Natalizumab VH (threshold 0.95)
QVQLVQSGAELKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQGLEWAGWIDPANGYTKYDPKFQGRVTITADTSINTAYLELSSLRSDDTAIYYCAREGYYGNYGVYAMDYWGQGTLVTVSS
>Natalizumab VL (threshold 0.499)
DIQMTQSPSSLSASLGGKVTITCKTSQDINKYMAWYQHTPGKGPRLLIHYTSALQPGIPSRFSGSGSGRDYSFSISNLEPEDIATYYCLQYDNLWTFGGGTKLEIK
>Nemolizumab VH (threshold 0.93)
EVQLVQSGAEVKKPGASVKMSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYAPQFQDRVTLTSDKSISTAYMELSSLTSEDSAVYDCARDGYDDGPYTLETWGQGTLLTVSS
>Nemolizumab VL (threshold 0.645)
DIQMTKSPASLSASVGETVTITCQASEDIYSFVAWYQQKQGKSPQLLVYNAQTEAQGVPSRFSGSGSGTQFSLKISSLQPEDFGSYYCQHHYDSPLTFGAGTKLELK
>Nimotuzumab VH (threshold 0.775)
QVQLAQSGAEVKKPGASVKLSCKASGYTFTNYYIYWVRQAPGQGLEWMGGINPTSGGSNFAEKFQTKATLTVDKSSSTAYMELSSLTSEDSAFYYCTRQGLWFDSDGRGFDFWGQGTTLTVSS
>Nimotuzumab VL (threshold 0.6859999999999999)
DVLMTQTPLSLPVSLGDQASISCRSSQNIVHSNGNTYLDWYLQTPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQYSHVPWTFGGGTKLQIT
>Obinutuzumab VH (threshold 0.83)
QVQLVQSGPEVKKPGASVKVSCKASGYAFSYSWINWVRQAPGQGLEWIGRIFPGDGDTDYAGKFQGKLTLTWDKSTSTAYMHLSSLTSVDSAVYFCARNVFDGYWLVYWGQGTLVTVSS
>Obinutuzumab VL (threshold 0.562)
DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIK
>Ocaratuzumab VH (threshold 0.805)
QVQLVQSGAEVKRPGASVKVSCKASGRTFTSYNMHWVRQAPRQGLEWIGAIYPLTGDTSYAQKSQLKATLTVDKSISTAYMQLSSLTSEDTAVYFCARSTYVGGDWQFDVWGTGTTVTVSS
>Ocaratuzumab VL (threshold 0.91)
QIVLSQSPAILSATPGEKATMACSASSSVPYIHWYQQLPGSSPKPWIYATSALASGIPARFSGSGSGTSYSLGISRVEAEDAATYYCQQWLSNPPTFGGGTKLEIK
>Ocrelizumab VH (threshold 0.78)
QVQLVQSGAEVKRPGASVKVSCKASGYTFTSYNMHWVRQAPRQGLEWIGAIYPGNGDTSYAQKFQGKATLTVDKSISTAYMQLSSLTSEDTAVYFCARVVYYSNSYWYFDVWGTGTTVTVSS
>Ocrelizumab VL (threshold 0.862)
QIVLSQSPAILSASPGEKVTMTCSASSSVSYMHWYQQLPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRLEAEDAATYYCQQWSFNPPTFGGGTKLEIK
>Olendalizumab VH (threshold 0.895)
QVQLVQSGPEVKKPGASVKVSCKASGYTFTDYSMDWVRQAHGQSLEWIGWIHLNTGYTNYAQKFQGRLTLNVDKSISTAYMELRSLTSEDSAVYYCARGFYDGYSPMDYWGQGTSVTVSS
>Olendalizumab VL (threshold 0.816)
DIVLTQSPASLAVTLGQRATISCRASESVDSYGNSFMHWYQQLPGQPPKLLIYRASNLESGVPARFSGSGSRTDFTLAISPVEADDVATYYCQQSNEDPYTFGGGTKLEIK
>Omalizumab VH (threshold 0.845)
EVQLLESGGGLVQPGGSLRLTCSVTGYSITSGYSWNWIRQAPGNKLEWMHSITYDGSTNYADSVKGRVSITRDTSKNQFFLKMNSVTAEDTAVYYCARGSHYFGHWHFAVWGTGTTVTVSS
>Omalizumab VL (threshold 0.8740000000000001)
DIVLTQSPASLAVALGQRATISCRASQSVDYDGDSYMNWYQQLPGQAPKLLIYAASYLESGIPARFSGSGSGTDFTLNIHPLEEEDAATYYCQQSHEDPYTFGGGTKLEIK
>Onartuzumab VH (threshold 0.725)
QVQLVQSGPEVKRPGASVKMSCTASGYTFTSYWLHWVRQAPGQGLEWIGMIDPSNSDTRFAPNFFDKVTLNWDKSSNTAYMDLSSLTSEDTAVYYCATYRSYVTPLDYWGQGTTLTVSS
>Onartuzumab VL (threshold 0.73)
DIVMSQSPSSLAVAVGEKVTMSCKSSQSLLYTSSQKNYLAWYQQLPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQQYYAYPWTFGGGTKLEIK
>Oportuzumab VH (threshold 0.455)
QIQLVQSGGEVKKPGETVRISCKASGYTFTNYGMNWVKQAPGKALKWMSWINTYTGESTYADSVKGRFAFSLEPSKSAAYLQINNLNNEDTAVCFCARFAIKGDYWGQGTTLTVSS
>Oportuzumab VL (threshold 0.787)
DIVMTQVASSNPVTLGTSASISCRSTKSLLHSNGITYLYWYLQHPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLEIPRTFGGGTKLELK
>Otlertuzumab VH (threshold 0.815)
QVQLVQSGAEVKKPGASVKISCKASGYSFTGYNMNWVRQANGKSLEWIGNIDPYYGGTTYARKFQGRVTLTVDKSISTAYMQLKSLTSEDSAVYYCARSVGPFDSWGQGTTLTVSS
>Otlertuzumab VL (threshold 0.98)
SIQMTQSPASLSVSVGETVTITCRASENVYSYLAWYQQKQGQSPQLLVYFAKTLAEGVPSRFSGSGSGTQFTLKINSVQPEDFGSYYCQHHSDNPWTFGGGTKLEIK
>Ozanezumab VH (threshold 0.63)
QVQLQQSGTELKKPGASVKLSCKASGYTFTSYWMHWVRQAPGQGLEWMGNINPSNGGTNYAEKFQSKVTLTVDKSMSTAYMELSSLTSEDSAVYYCELMQGYWGQGTTLTVSS
>Ozanezumab VL (threshold 0.586)
DIVITQDELSNPVTSGESVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGSGSGTDFTLEISRVKAEDVGVYYCQQLVEYPLTFGAGTKLELK
>Palivizumab VH (threshold 0.885)
QVTLRVSGPTLVKPTQTLTLTCSFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSQLTISKDTSRNQVVLTITNVDPADTATYYCARSMITNWYFDVWGAGTTVTVSS
>Palivizumab VL (threshold 0.8759999999999999)
SIVLTQTPAIMSVSPGEKVTMTCKCQLSVGYMHWYQQKSSTSPKLWIYDTSKLASGVPGRFSGSGSGNSYTLTISSMEAEDVATYYCFQGSGYPFTFGSGTKLEIK
>Parsatuzumab VH (threshold 0.815)
QVQLVQSGPEVKKPGASVKVSCKASGYTFTDYYMNWVRQAHGKSLEWMGDINLDNSGTHYAQKFHGKLTLTVDKSISTAYMDLSSLTSEDSAVYYCAREGVYHDYDDYAMDYWGQGTSVTGSS
>Parsatuzumab VL (threshold 0.8190000000000001)
DVVMTQTPLSLPVALGDRASISCRTSQSLVHINAITYLHWYLQLPGQSPKLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCGQSTHVPLTFGAGTKLELK
>Pateclizumab VH (threshold 0.69)
EVQLVESGPEVKKPGASVKMSCKASGYTFTSYVIHWVRQAPGQGLEWIGYNNPYNAGTNYNEKFQGRVTLTSDKSISTAYMELSSLTSEDTAVYYCSRPTMLPWFAYWGQGTLVTVSA
>Pateclizumab VL (threshold 0.9620000000000001)
SIVITQSHKFMSVSVGDRVSITCRANQAVSSAVAWYQQKPGQSPKLLIYSASHRYTGVPDRFTGSGSGTTFTFTISSVQAEDLAVYYCQESYSTPWTFGGGTKLEIK
>Pembrolizumab VH (threshold 0.88)
QVQLVQSGVEVKKPGVSVKLSCKASGYTFTNYYMYWVRQAPGQDLEWMGGINPSNGGTNFAEKFQNRATPTVDSSISTAYMELKSLQFEDSAVYFCARRDYRFDMGFDYWGQGTTLTVSS
>Pembrolizumab VL (threshold 0.87)
DSALTQSPASLAGSLGQSATISCRASKGVSTSGYSYLHWYQQHPGQPPKLLIYLASYLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRDLPLTFGGGTKLEIK
>Perakizumab VH (threshold 0.955)
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYTMLWVRQAPGKGLEWVSIIKSGGSYSYYVDSVKGRFTISRDNAKNNLYLQMNSLRVEDTAMYYCARDGDYGSSYGAMDYWGQGTLVTVSS
>Perakizumab VL (threshold 0.568)
DIKMTQSPSSMYASLGERVTITCRASQDINSYLSWFQQKPGKSPKTLIVRANRLVDGVPSRFSGSGSGQDYSLTISSLEYEDRGIYYCLQYDAFPPYTFGGGTKLEIK
>Pertuzumab VH (threshold 0.875)
QVQLVESGPEVKKPGASVKVPCKASGYTFTDYTMDWVRQAHGQSLEWIGDVNPNSGGSIYAQRFQGRVTLTVDKSISTAYMELRSLTSEDTAVYYCARNLGPSFYFDYWGQGTTLTVSS
>Pertuzumab VL (threshold 0.888)
SIVMTQSHKFMSVSVGDRVSITCKASQDVSIGVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQYYIYPYTFGGGTKLEIK
>Pidilizumab VH (threshold 0.595)
QIQLVQSGAEAKKPGSSVKVSCKASGYTFTNYGMNWVRQAPGKGLQWMGWINTDSGESTYAEEFQGRFVMSLETSVSTAYMDINNLKNEDTATYFCVRVGYDALDYWGQGTSVTVSS
>Pidilizumab VL (threshold 0.63)
QIVLTQSPAIMSASPGEMVTITCSARSSVSYMHWFQQKPGTSPKLWIYRTSNLASGVPARFSGSGSGTSYCLTISRMEAEDAATYYCQQRSSFPLTFGAGTKLELK
>Pinatuzumab VH (threshold 0.86)
EVQLVQSGPEVKKPGASVKVSCKASGYEFSRSWMNWVRQAPGKGLEWMGRIYPGDGDTNYAGKFQGRLTLTADKSSSTAYMELSSLTSEDSAVYFCARDGSSWDWYFDVWGTGTTVTVSS
>Pinatuzumab VL (threshold 0.741)
DSLMTQTPLSLPISLGDQASISCRSSQSIVHSVGNTFLEWYLQHPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSQFPYTFGGGTKLEIK
>Pogalizumab VH (threshold 0.825)
QLQLVQSGPEVKEPGASMKVSCKASGYTFTDSYMSGVRQSHGKSLEWMGDMYPDNGDSSYAQKFQESATLTVDRSISTAYMELDSLTSEDTAAHYCVLAPRWYFSVWGAGTTVTVSS
>Pogalizumab VL (threshold 0.674)
SIQMTQTPSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLRSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGHTLPPTFGGGTKLEIK
>Polatuzumab VH (threshold 0.69)
QVQLGQPGAEVKKPGASVKISCKATGYTFSSYWIEWVRQAPGHGLEWIGEILPGGGDTNYAEIFQGEATFTWDTSINTAYMDLSSLTSEDTAVYYCARRVPIRLDYWGQGTLVTVSA
>Polatuzumab VL (threshold 0.8590000000000001)
DIVMTQSPASLAVTLGQRATISCKASQSVDYEGDSFLNWFQQLPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLNIHPLEEEDAATYYCQQSNEDPLTFGAGTKLELK
>Prasinezumab VH (threshold 0.875)
QVQLVESGGGLVQPGRSLRLSCAASGFTFSNYGMSWVRQTPGKGLEWVASISSGGGSTYYADNVKGRFTISRDNSKNTQYLQMDSLRVEDTAVYYCARGGAGIDYWGQGTLVTVSS
>Prasinezumab VL (threshold 0.645)
SIVMSQSPSSLAVSVREKVTMSCKSIQTLLYSSNQKNYLAWYQQKPGQSPVLLIYWASIRKSGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK
>Quilizumab VH (threshold 0.8)
QVQLVQSGGEVKQPGGSLKVSCKASGFTFSDYGIAWVRQAPRQGPEWMAFISDLAYTIYYAQTCQGRFTISRENASNTLYLEMSSLRSEDTAMYYCARDNWDAMDYWGQGTSVTVSS
>Quilizumab VL (threshold 0.759)
DSVMTQTPLSLPVSLGDQASISCRSSQSLVHNNANTYLHWYLQHPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCSQNTLVPWTFGGGTKLEIK
>Ralpancizumab VH (threshold 0.875)
QVQLVQSGAEVKKPGASVKLSCKASGYTFTSYYMHWVRQAPGQGLEWIGEIHPSGGRTNYAEKFQSRATMTVDKSISTAYMALSSLTSEDTAVYYCARERPLYASDLWGQGTSVTVSS
>Ralpancizumab VL (threshold 0.872)
SIVMTQSHKSMSTSVGDRVSITCKASQDVHTAVAWYQQKPGQSPKLLIYHASYRYTGVPGRFTGSGSGTDFTFTISSVQAEDLAVYYCQQRYSLWRTFGGGTKLEIK
>Ranibizumab VH (threshold 0.805)
QIQLVQSGAEVKKPGSSVKVSCKASGYDFTHYGMNWVRQAPGNGLKWMGWINTYTGEPTYAAKFQRRVAMTLETSASTAYLEIRNLKNEDMATYFCARYPYYYGTSHWYFDVWGAGTTVTVSS
>Ranibizumab VL (threshold 0.914)
DIQMTQTTSSLSAALGDRVTISCSASQDISNYLNWYQQLPDGTVKLLIYFTSSLHSGVPSRFSGSGSGTSYFLCISNLEPEDIATYYCQQYSTVPWTFGGGTKLEIK
>Ravulizumab VH (threshold 0.975)
QVQLVQSGAEVMKPGASVKVSCKATGHTFSNYWIQWVRQAPGQGLEWMGWILPGSGHTEYAENFQDRATFTADTSINTAYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGAGTTVTVSS
>Ravulizumab VL (threshold 0.893)
SIQMTQSPASLSVSVGETVTITCGASENIYGALNWYQRKQGQSPQLLIYGATNLADGMSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLNTPLTFGAGTKLELK
>Refanezumab VH (threshold 0.88)
QVQLVQSGSEWKKPGASVKVSCKASGYTFTNYGMNWVGQAPGQGLEWMGWINTYTGEPTYAQGFTGRFVFSLETSVSTAYLQINNLKAEDTAVYFCARNPINYYGINYEGYVMDYWGQGTLVTVSS
>Refanezumab VL (threshold 1.0)
QSAMTQPASSLAGSAGEKVTISCAGDHSVLYSSNQKNYLPWYQQHPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCHQYLSSLTFGEGTKLELK
>Reslizumab VH (threshold 0.76)
QVQLKQSGSELKQPSASLSVTCTVSGLSLTSNSVNWIRQAPGQGLEWMGWIWSNGDTDYAQAITGRLVFSRDTSVSQVFLKINSLQAEDTAMYFCAREYYGYFDYWGQGVLVTVSS
>Reslizumab VL (threshold 0.7909999999999999)
SIVLTQSPSSMYSSLGERVTITCLASEGISSYLAWFQQKPGKSPVTLISGANSLQTGVPSRFSGSGSAQDYTLTISSLDYEDVGIYYCQQSYKFPNTFGGGTKLEVK
>Risankizumab VH (threshold 0.77)
QVQLVQSDAEVRKPGASVKISCKVSGYTFTDQTIHWMRQAPEQGLEWMGYIYPRDDSPKYAENFLGKVTLTADKSSSTAYMELNSLTSEDYAVYFCAIPDRSGYAWFIYWGQGTLVTVSA
>Risankizumab VL (threshold 0.6759999999999999)
DIVMTQSHKFMSTSVGDRVSITCKASRDVAIAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSRTDFTLTISNVQSEDLADYFCHQYSSYPFTFGSGTKLEIK
>Rivabazumab VH (threshold 0.995)
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVISYDGSEKWYADSVKGRFTISRDNAKSTLYLQMNSLRAEDTAVYYCTRNRGDIYYDFTYAMDIWGQGALVTVSS
>Rivabazumab VL (threshold 0.976)
SIQMTQSPASVSVSVGETATITCRADEGVDRWLAWYQQKQGRSPQLLIYDASTLQSGIPSRFSGSGSGTQYTLKINSVQSEDLGSYYCQHFWGTPYTFGGGTKLEIK
>Romosozumab VH (threshold 0.88)
QVQLVQSGPEVKKPGASVKIPCKASGYTFTDYNMHWVRQAHGKSLEWMGEINPNSGGAGYAQKFQGRATLTTDKSISTAYMELRSLTSEDTAVYYYARLGYDDIYDDWYFDVWGTGTTVTVSS
>Romosozumab VL (threshold 0.696)
DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQLPDGTVKLLIYYTSRLLSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGDTLPYTFGGGTKLEIK
>Rontalizumab VH (threshold 0.83)
EVQLAQSGPEVKKPGASVKVSCKASGYTFTEYIIHWVRQAPGQGLEWMGSINPDYDITNYAQRFQGRATLTSDKSSRTAYMELSSLTSEDSAVYYCASWISDFFDYWGQGTSVTVSS
>Rontalizumab VL (threshold 0.8)
DIVLTQSPASLAVTLGQRATISCRASQSVSTSSYSYMHWYQQLPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVQEEDTATYYCQHSWGIPRTFGGGTKLEIK
>Rosmantuzumab VH (threshold 0.815)
QVQLVQSGPELKKPGASVKVSCKASGYTFTDYSIHWVRQAPGQGLEWIGYIYPSNGDSGYAQKFQNKATLTVDTSISTAYMELSSLTSDDTAVYFCATYFANNFDYWGQGTTLTVSS
>Rosmantuzumab VL (threshold 0.6409999999999999)
DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTKLELK
>Rovalpituzumab VH (threshold 0.975)
QVQLVQSGGEGKKPGSTVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMAIINTYTGEPTYAQKFQGRVAMTTATSTSTAYAELSNLKSEDMAVYFCARIGDSSPSDYWGQGTTLTVSS
>Rovalpituzumab VL (threshold 0.98)
SYELTQTSKFLSVSAGDRVTISCKASQSVSNDVVWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSGYGTTFTFTISTVQAEDLAVYFCQQDYTSPWTFGGGTKLEIK
>Ruplizumab VH (threshold 0.245)
QVQLKQSGAEVNKPGASVKLSCKASGYTFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFQSKATLTVDKSISTAYMQLSSLTSEDSAVYYCTRSDGRNDMDSWGQGTSVTVSS
>Ruplizumab VL (threshold 0.25)
DIVLTQSPASLAVSLGLRATISCRASQRVSSSTYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVEEEDTATYYCQHSWEIPPTFGGGTKLEIK
>Sacituzumab VH (threshold 0.45)
QIQLVQSGPEVKKPGSTVKVSCKASGYTFTNYGMNWVRQAPGKGLKWMGWINTYTGEPTYTDKFKGRVAMSLETSVSTAYMQINNLKNEDTATYFCARGGFGSSYWYFDVWGAGSTVTVSS
>Sacituzumab VL (threshold 0.716)
DIVMTQSHKFMSTSVGDRVSITCKASQDVSIAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFSGSGSGTDFTFTISSVQADDLAVYYCQQHYITPLTFGAGTKLEIK
>Samalizumab VH (threshold 0.355)
QVQLIQTGPELKKPGASVKISCKASGYSFTDYIILWVKQNHGKSLEWIGHIDPYYGSSNYALKFQGKATLTVDQSISTAYMELNSLTSEDSAVYYCGRSKRDYFDYWGQGTTLTVSS
>Samalizumab VL (threshold 0.489)
DIQMTQSPSSLSASIGERVTITCKASQDINSYLSWFQQKPGKSPKTLIYRANRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPYTFGGGTKLEIK
>Sapelizumab VH (threshold 0.79)
QAQLQQSGPGLVKPSQTIFLACAISGHSITHDHAWNWIVQSPSRGLEWLGRISYSGITEYAISVGGRIAINPDTSNNEFSLQLNSVTPEDTAVYYCARSLARTTAMDYWGEGTAVTVSS
>Sapelizumab VL (threshold 0.748)
DSQMTQTTSSLSASLRDSVTISCQASTDISSHLSWYQQHPDGTVKLLIYYGSHLLSGVPSRFSGSGSGTDYSLTISNLEQEDAATYFCGQGNRLPYTFGGGTKLEIE
>Satralizumab VH (threshold 0.79)
QAQLQQSGPGLVKPSQTIFLACAISGHSITHDHAWNWIVQSPSRGLEWLGRISYSGITEYAISVGGRIAINPDTSNNEFSLQLNSVTPEDTAVYYCARSLARTTAMDYWGEGTAVTVSS
>Satralizumab VL (threshold 0.748)
DSQMTQTTSSLSASLRDSVTISCQASTDISSHLSWYQQHPDGTVKLLIYYGSHLLSGVPSRFSGSGSGTDYSLTISNLEQEDAATYFCGQGNRLPYTFGGGTKLEIE
>Simtuzumab VH (threshold 0.705)
QVQLVQSGAEVKRPGTSVKVSCKASGYAFTYYLIEWVRQAPGQGLEWIGVINPGSGGTNYAEKFQGKATLTADKSTSTAYMQLSSLTSEDTAVYFCARNWMNFDYWGQGSTLTVSS
>Simtuzumab VL (threshold 0.6)
DIVMTQAAPSLPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQKPGQSPQFLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPYTFGGGTKLEIK
>Sofituzumab VH (threshold 0.795)
QVQLVQSGPGVKKPGASVSVTCTVTGYSITNDYAWNWIRQAPGQKLEWMGWISYSGYTTYAPKLKSRISITRDTSTNTFFLDLNSVTTEDTATYYCARWTSGLDYWGQGTTLTVSS
>Sofituzumab VL (threshold 0.804)
SIQMTQSSSSLSVSLGGRVTITCKASDLIHNWLAWYQQKPGNAPRLLISGATSLETGVPSRFSGSGSGEDYTLSIISLQTEDVATYYCQQYWTTPFTFGSGTKLEIK
>Solanezumab VH (threshold 0.855)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVSQINSVGNSTYYADTVKGRFTISRDNAKNTLYLQLSSLKTEDTAIYYCARGDYWGQGTQVTVSS
>Solanezumab VL (threshold 0.888)
DSAMTQPALSLPVSLGDQTSISCRSSQSLIYSDGNAYLHWYLQHPGQSPELLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIK
>Spartalizumab VH (threshold 0.815)
QVQLVQPGAEVKKPGASVKVSCKASGYTFTTYWMHWVRQAPGQGLEWMGNIYPGTGGSNFDEKFQNKVTLTVDTSISTAYMELSSLTSEDSAVYYCTRWTTGTGAYWGQGTLVTVSA
>Spartalizumab VL (threshold 0.76)
DIVMTQSPSSLTVTPGEKVTLSCKSSQSLLDSGNQKNFLTWYQQLPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDAAVYYCQNDYSYPYTFGGGTKLEIK
>Suvizumab VH (threshold 0.615)
QVQLIQSGAEVKRPGTSVKISCKASGYTFTNSWIGWVRQAPGHGLEWMGDIYPGGGYTNYAEIFQGKATLTADTSISTAYMQLSSLTSEDSAVYFCSRGIPGYAMDYWGQGTSVTVSS
>Suvizumab VL (threshold 0.68)
DIVMTQRPSSLSVSAGEKVTMSCKSSQSLLNSGDQKNYLTWYQQLPGQPPKLLIYWASTGESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPWTFGGGTKLEIK
>Tadocizumab VH (threshold 0.755)
QVQLVESGAEVKRPGTSVKVSCKASGYAFTNYLIEWVRQAPGQGLEWIGVIYPGSGGTNYAEKFQGRATLTADKSISTAYMDLSSLTSDDSAVYFCARRDGNYGWFAYWGQGTLVTVSA
>Tadocizumab VL (threshold 0.7120000000000001)
DIQMTQTTSSLSASLGDRVTISCRASQDINNYLNWYQQLPDGTVKLLIYYTSTLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEVK
>Talacotuzumab VH (threshold 0.815)
QVQLVQSGPEGNKPGASVKMSCKASGYTFTDYYMKWARQAHGKSLEWMGDIIPSNGATFYAQKFQGRVTLTWDKSISTTYMELDSLTSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSA
>Talacotuzumab VL (threshold 0.935)
DIVMTQSPSSLAVAAGEKVTMSCEGSQSLLNSGNQKNYLTWYQQLPGQPPKPLIYWASTRESGVPDRFTGSGSGTDFTLAISSLQAEDLAVYYCQNDYSYPYTFGGGTKLEIK
>Tanezumab VH (threshold 0.855)
QVQLVDSGPEVKKPGASLKVTCQVSGFSLTGYDLNWVRQAPGQGLEWLGIIWGDGTTDYAQKVQSRLSITKDNSKSQVFLEMNSLQTDDTARYYCARGGYWYATSYYFDYWGQGTTLTVSS
>Tanezumab VL (threshold 0.8859999999999999)
DIVMTQTTSSLSATLGDRVTISCSASQSISNNLNWYQQLPDGTVKLLIYYTSRFHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQEHTLPYTFGGGTKLEIK
>Telisotuzumab VH (threshold 1.0)
QVQLIQSGAEVKKPGSSVKVSCKTSGYTFTAYTAHWVRQAHGKSLEWMGWIKPNNGLANYAQKFQGAVTLTRDKSISTAYMELLSLTSEDTAVYYCARSEITTEFDYWGQGTTLTVSS
>Telisotuzumab VL (threshold 0.92)
QIVLTQSPASLAVSPGQRATISCKSSESVDSYANSFLHWYQQLPGQPPKLLIYRASTRESGIPARFSGSGSRTSFTLGINPVEADDVATYYCQQSKEDPLTFGAGTKLELK
>Teplizumab VH (threshold 0.695)
QVQLVQSGAEVNRPGASVKVSCKASGYTFTRYTMHWVRQAPGQGLEWMGYINPSRGYTNYAQKVQDKATLTWDKSISTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTPVTVSS
>Teplizumab VL (threshold 0.716)
SIVMTQSTSSLSVSAGEKVTITCSASSSVSYMNWYQQTSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPFTFGSGTKLQIT
>Tibulizumab VH (threshold 1.0)
QVQLQESGPGLVKPSETLSLTCAVSGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISTDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGVLVTVSS
>Tibulizumab VL (threshold 1.0)
QTVLTQSPATMSAYPGCKVTVTCSVSQSVSRYLAWYQQLPGSSPKLRIFDASNRATGVPARFSGSGSGTSASLDISSLEAEDAASYFCQQRSNWPRTFGGGTKLEIK
>Tigatuzumab VH (threshold 0.85)
QVQLVQSGAGVKKPGASLKVSCQASGFTFSSYVMSWVRQAPEPRLEWMGWISSGGSYTYYPQKVKGRFTISRDAATNTAYLDMSSLRSEDTAVYYCARRGDSMITTDYWGQGTTLTVSS
>Tigatuzumab VL (threshold 0.8420000000000001)
SIVMTQSPKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYRTFGGGTKLEIK
>Tildrakizumab VH (threshold 0.9)
QVQLEQSGPEVKRPGASVKLSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYAEKFQGRVTLTVDTSISTAYMDLSSLRSEDSAVYYCARGGGGFAYWGQGTLVTVSS
>Tildrakizumab VL (threshold 0.522)
DIQMTQSPASLSAFVGETVTITCRTSENIYSYLAWYQQKQGKSPQFLVYNAKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHHYGIPFTFGSGTKLEIK
>Timigutuzumab VH (threshold 0.965)
EVQLMESGGALVAPGGSLRLSCTASGFNIKDTYIHWVRQAPGQGLEWISRIYPTNGYTRYADSVKGRCTISRDTSSNTAYLQMSSLRVEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
>Timigutuzumab VL (threshold 0.777)
SIMMTQSHKFMSTSVGDRVSITCRASQDVNTAVAWYQQKPGHSPKLLIYSASFLYSGVPDRFTGSRSGTDFTFTINSVQAEDLAVYYCQQHYTTPPTFGGGTKLEIK
>Tislelizumab VH (threshold 0.845)
QVQLQEWGPGLVAPSETLSLTCTVSGFSLTSYGWHWVRQPPGKGLEWIGVIYADGSTNYNPSLKSRVSISVDNSKSQVSLKMNSVTAADTAMYYCARAYGNYWYIDVWGAGTTVTVSS
>Tislelizumab VL (threshold 0.905)
SIVMTQTPKFLLVSAGDRVTITCKSSESVSNDVAWYQQKPGQSPKLLINYAFHRFTGVPDRFTGSGYGTDFTFTISTVQAEDLAVYFCHQAYSSPYTFGGGTKLEIK
>Tocilizumab VH (threshold 0.935)
QCQLVESGPEVKRPGASVKVTCTVTGYSITSDHAISWIRQCPGQKLEWMGWISYSGITTYAPKLQSRVSMLRDTSINQFFLELNSVTTEDTATYYCARSLARTTAMDYWGQGSLVTVSS
>Tocilizumab VL (threshold 0.65)
DIQMTQTTSSLSASLGDRVTISCRASQDISSYLNWYQQLPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEIK
>Trastuzumab VH (threshold 0.965)
EVQLMESGGALVAPGGSLRLSCTASGFNIKDTYIHWVRQAPGQGLEWISRIYPTNGYTRYADSVKGRCTISRDTSSNTAYLQMSSLRVEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
>Trastuzumab VL (threshold 0.777)
SIMMTQSHKFMSTSVGDRVSITCRASQDVNTAVAWYQQKPGHSPKLLIYSASFLYSGVPDRFTGSRSGTDFTFTINSVQAEDLAVYYCQQHYTTPPTFGGGTKLEIK
>Tregalizumab VH (threshold 0.93)
EEQLVETGGGLVRPGGSLRLSCVASGFTFSDCRMYWLRQAPGKRLVWVSVISVKSENYGANYAESVRGRFTISRDDSKNSVYLQMNSLREEDTAVYYCSASYYRYDVGAWFAYWGQGTLVTVSS
>Tregalizumab VL (threshold 0.855)
DIVLTQSPDSLAVTLGQRATISCRASKSVSTSGYSYIYWYQQLPGTPPKLLIYLASILESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPWTFGGGTKLEIK
>Vandortuzumab VH (threshold 0.8)
QVQLAQSGAGVKKPGASLSVTCTVSGYSITSDYAWNWIRQAPGQKLEWMGWISNSGSTSYAPKLKSRISITRDTSKNTFFLDLNSVTTEDTATYYCARERNYDYDDYYYAMDYWGQGTSVTVSS
>Vandortuzumab VL (threshold 0.725)
DIVMTQSPSSLAMTVGQKVTMSCKSSQSLLYRSNQKNYLAWYQQLPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYNYPRTFGGGTKLEIK
>Vatelizumab VH (threshold 0.595)
QVQLQQSGPGLVCPSQTLSLTCDISGFSLTNYGWNWVRQSPSRGLEWLGRIWARGFTNYAVAVMSRISINPDTSKSQFSLKLNSVTPDDTAMYYCARANDGVYYAMDYWGQGTTVTVSS
>Vatelizumab VL (threshold 0.268)
DFVMTQSPAIMSASPGEKVTITCSAQSSVNYIHWYQQKSDTSPKKWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWTTNPLTFGAGTKLELK
>Vedolizumab VH (threshold 0.795)
QVQLVQPGAEVKKPGASVKLSCKASGYTFTSYWMHWVRQAPGQGLEWMGEIDPSESNTNYAQKFQGKATLTWDISMSTAYMELSSLTSEDSAVYYCARGGYDGWDYAIDYWGQGTSVTVSS
>Vedolizumab VL (threshold 0.83)
DVVVTQTPLSLPVTFGDQVSISCRSSQSLAKSYGNTYLSWYLQLPGTSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISTIKPEDLGMYYCLQGTHQPYTFGGGTKLEIK
>Veltuzumab VH (threshold 0.415)
QVQLQQPGAELKKPGASVKMSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGMGDTSYAQKFQGKATLTADKSISTAYMELSSLTSEDSAFYYCARSTYYGGDWYFDVWGAGTTVTVSS
>Veltuzumab VL (threshold 0.6990000000000001)
SIVLTQSPAILSASPGEKVTMTCRASSSVSYIHWYQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISSMEAEDAATYYCQQWTSNPPTFGGGTKLEIK
>Visilizumab VH (threshold 0.685)
QVQLVQSGAEVNKPGASVKVSCKASGYTFTSYTMHWVRQAPGQGLEWIGYINPRSGYTHYAQKLQDRATLTWDKSMSTAYMQLSSLTYEDSAVYYCARSAYYDYDGFAYWGQGTLVTVSA
>Visilizumab VL (threshold 0.848)
DIVLTQTPSSLSATLGDRVTMTCSASSSVSYMNWYQQLSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGGGTKLEIK
>Vonlerolizumab VH (threshold 0.825)
QLQLVQSGPEVKEPGASMKVSCKASGYTFTDSYMSGVRQSHGKSLEWMGDMYPDNGDSSYAQKFQESATLTVDRSISTAYMELDSLTSEDTAAHYCVLAPRWYFSVWGAGTTVTVSS
>Vonlerolizumab VL (threshold 0.674)
SIQMTQTPSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLRSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGHTLPPTFGGGTKLEIK
>Vorsetuzumab VH (threshold 0.965)
QGQLVQSGAAVKKPGSSVKVSCKASGYTFTNYGINWVRQAPGNGLKWMGWINTYTGEPTYAQKFKGRVAMTTDTSIDTAYLDLCNLRNEDTAVYFCARDYGDYGMDYWGQGTSVTVSS
>Vorsetuzumab VL (threshold 0.7)
DIVLTQSPDSLAVSLGQRATISCRASKSVSTSGYSFMHWYQQLPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSREVPWTFGGGTKLEIK
>Vunakizumab VH (threshold 0.91)
EVQVVQSGAEVKRPGASVTVSCKASGYTFTDYEVHWVRQAPVHGLEWLGVIDPGTGGVAYAQKFEGRVILTADKSISPAYLELRSLTSEDTAVYYCTRYSLFYGSSPYAMDYWGQGTSVTVSS
>Vunakizumab VL (threshold 0.605)
EIVITQTTAIQSASPKEKVTITCSASSSVNYMHWYQQKSDASPKPWIYRTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPWTFGGGTKLEIK
>Zenocutuzumab VH (threshold 1.0)
QVQLIQSGPEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQSLEWMGWINPNSGGTNYAQKFQGRLTLTADKSSSTAYMELRSLTSEDTAVYYCARDHGSRHFWSYWGFDYWGTGTTVTVSS
>Zenocutuzumab VL (threshold 1.0)
SIVLTQSPATLSVTPGDRATLACSANQSISSYLNWYQQKSGQSPRLLIKAASSLQSGVPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSYSTPPTFGVGTKLELK
